EU Rules Could Restrict Genetic Testing

  • database,DNA,genetic testing,genetics
  • thelatestnews

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments. Testing is via a blood or tissue sample. With best practice, counseling may be required, depending on the test outcome.

Draft European regulations governing the use of medical devices could lead to a restriction in genetic testing. This would be limiting genetic tests to a narrower range of scenarios.

The restrictions are not supported by medical research backers. A group got together to express concerns that the proposals would limit the availability of genetic testing, and this would not be to the benefit of society.

According to the U.K. Medical Research Council, genetic tests are being considered as the European Union redraws the rules governing the manufacture and sale of all medical devices, including in vitro diagnostic devices. This covers the range from blood glucose monitoring kits for diabetes and home pregnancy tests, to complex hospital assays.

The new rules carry a proposed stipulation that genetic tests should only be conducted by a qualified medical professional and after a prescription has been signed-off.

Some scientists are concerned that this will stop the practice of blood being sampled at birth, by a healthcare professional, to screen for genetic disorders. There are also concerns that these limitations will hamper disease research.

An example of such research is the 100,000 Genomes Project. This is a complex and technically challenging project, to enable the U.K. National Health Service (NHS) to offer genomic medicine to those patients who need it in the future. The project also aims to create a national resource of sequence data linked to clinical records. This would include cancer samples.

These concerns suggest that the European Union proposals need re-examining.

This link:http://www.chemcd.com/news/19770.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.